Boster A[au] - Search Results

Year	Number of Results
2008	3
2009	4
2010	2
2011	2
2012	1
2013	4
2014	4
2015	4
2016	5
2017	1
2018	1
2019	6
2020	6
2021	3
2022	1

1

Best Practices for Intrathecal Baclofen Therapy: Troubleshooting.

Saulino M, Anderson DJ, Doble J, Farid R, Gul F, Konrad P, Boster AL. Saulino M, et al. Among authors: boster al. Neuromodulation. 2016 Aug;19(6):632-41. doi: 10.1111/ner.12467. Epub 2016 Jul 19. Neuromodulation. 2016. PMID: 27434299 Review.

2

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.

Olsson T, Boster A, Fernández Ó, Freedman MS, Pozzilli C, Bach D, Berkani O, Mueller MS, Sidorenko T, Radue EW, Melanson M. Olsson T, et al. Among authors: boster a. J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1198-208. doi: 10.1136/jnnp-2013-307282. Epub 2014 Mar 21. J Neurol Neurosurg Psychiatry. 2014. PMID: 24659797 Free PMC article. Clinical Trial.

3

Intracerebral haemorrhage during alemtuzumab administration.

Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Azevedo CJ, et al. Among authors: boster a. Lancet Neurol. 2019 Apr;18(4):329-331. doi: 10.1016/S1474-4422(19)30076-6. Epub 2019 Feb 15. Lancet Neurol. 2019. PMID: 30777657 No abstract available.

4

Best Practices for Intrathecal Baclofen Therapy: Screening Test.

Boster AL, Bennett SE, Bilsky GS, Gudesblatt M, Koelbel SF, McManus M, Saulino M. Boster AL, et al. Neuromodulation. 2016 Aug;19(6):616-22. doi: 10.1111/ner.12437. Epub 2016 Jul 19. Neuromodulation. 2016. PMID: 27434115 Review.

5

First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

Nicholas JA, Racke MK, Imitola J, Boster AL. Nicholas JA, et al. Among authors: boster al. Ther Adv Chronic Dis. 2014 Mar;5(2):62-8. doi: 10.1177/2040622313514790. Ther Adv Chronic Dis. 2014. PMID: 24587891 Free PMC article. Review.

6

Best Practices for Intrathecal Baclofen Therapy: Dosing and Long-Term Management.

Boster AL, Adair RL, Gooch JL, Nelson ME, Toomer A, Urquidez J, Saulino M. Boster AL, et al. Neuromodulation. 2016 Aug;19(6):623-31. doi: 10.1111/ner.12388. Epub 2016 Jul 19. Neuromodulation. 2016. PMID: 27433993 Review.

7

Best Practices for Intrathecal Baclofen Therapy: Patient Selection.

Saulino M, Ivanhoe CB, McGuire JR, Ridley B, Shilt JS, Boster AL. Saulino M, et al. Among authors: boster al. Neuromodulation. 2016 Aug;19(6):607-15. doi: 10.1111/ner.12447. Epub 2016 Jul 19. Neuromodulation. 2016. PMID: 27434197 Review.

8

Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.

Fox EJ, Buckle GJ, Singer B, Singh V, Boster A. Fox EJ, et al. Among authors: boster a. Neurol Clin Pract. 2019 Feb;9(1):53-63. doi: 10.1212/CPJ.0000000000000567. Neurol Clin Pract. 2019. PMID: 30859008 Free PMC article. Review.

9

Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

Boster AL, Ford CC, Neudorfer O, Gilgun-Sherki Y. Boster AL, et al. Expert Rev Neurother. 2015 Jun;15(6):575-86. doi: 10.1586/14737175.2015.1040768. Epub 2015 Apr 30. Expert Rev Neurother. 2015. PMID: 25924547 Review.

10

The potential role of B cell-targeted therapies in multiple sclerosis.

Boster A, Ankeny DP, Racke MK. Boster A, et al. Drugs. 2010 Dec 24;70(18):2343-56. doi: 10.2165/11585230-000000000-00000. Drugs. 2010. PMID: 21142258 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results